This clinical trial is focused on studying the safety and effects of a medication called fenfluramine hydrochloride in infants aged 1 to less than 2 years who have Dravet syndrome. Dravet syndrome is a rare and severe form of epilepsy that begins in infancy and is characterized by frequent and prolonged seizures. The medication being tested, known by the code name ZX008, is given as an oral solution and is intended to help manage seizures associated with this condition.

The purpose of the study is to evaluate how safe and tolerable fenfluramine hydrochloride is for young children with Dravet syndrome. Participants in the study will receive the medication for up to 52 weeks. During this time, researchers will monitor the children to see how the medication moves through their bodies and how it affects their health, including any changes in seizure frequency and overall well-being. The study will also look at any potential side effects, such as changes in heart function or growth patterns.

Throughout the study, the children will have regular check-ups to assess their health and development. These visits will help researchers gather important information about the medication’s impact on the participants. The study aims to provide valuable insights into the use of fenfluramine hydrochloride for treating Dravet syndrome in very young children, potentially offering a new option for managing this challenging condition.